Solas BioVentures

Francis Medical, Inc., established in 2018 and based in Maple Grove, Minnesota, specializes in the development of innovative medical devices utilizing water vapor technology to treat various urological cancers. The company focuses on prostate, kidney, and bladder cancers, aiming to provide minimally invasive treatments that can potentially reduce life-altering side effects common with traditional methods. Their approach involves using the thermal energy stored in sterile water vapor to ablate cancerous tissue via a simple transurethral procedure.

Vektor Medical, based in San Diego, focuses on enhancing the treatment of atrial fibrillation and other arrhythmias through its innovative technology. The company has developed vMap, an AI-based, non-invasive system that analyzes arrhythmia using a patient's electrocardiogram (ECG) to pinpoint the sources of abnormal heart rhythms. This FDA-cleared solution aims to enhance cardiac ablation outcomes, streamline workflows, and boost procedural efficiency for healthcare professionals.

Basking Biosciences is developing a reversible thrombolytic therapy to restore blood flow to the brain during ischemic stroke, with the aim of preventing hemorrhage and long-term damage. The platform combines a primary agent that targets clot stability with a designed reversal agent that can be administered if bleeding occurs to neutralize the active compound and restore normal clotting, enabling treatment for acute ischemic stroke.

Founded in 2015, Arrivo BioVentures specializes in developing biologics and small molecules to enhance patient care. The company focuses on efficient clinical programs, coordinating with regulatory bodies early on to expedite drug approvals.

Dimension Inx designs and develops advanced biomaterials for regenerative medicine. Founded in 2017, it specializes in creating microenvironments that guide the body's natural healing processes. Its platform focuses on the interplay between material composition, microstructure, and microarchitecture to produce biofunctional materials.

EirSystems Inc. is a medical software company established in 2018 and located in Chattanooga, Tennessee. It specializes in developing blockchain-based solutions to enhance the prescription process, particularly focusing on opioid prescriptions. The company's flagship product, the Prescription Abuse Greatly Reduced (P.A.G.R.) system, allows healthcare providers, including doctors and pharmacists, to accurately track the movement of prescriptions, write prescriptions efficiently, and conduct medicine reconciliation. By leveraging distributed ledger technology, EirSystems aims to reduce inefficiencies and improve interoperability in healthcare services, ultimately facilitating better management and oversight of prescription medications.

Stimdia Medical is a medical device company that specializes in developing a non-invasive lung pacing device aimed at facilitating the weaning process for patients on mechanical ventilation. By reducing the time required to transition patients off ventilators, the device not only enhances patient outcomes but also helps healthcare providers minimize associated health risks and costs. This innovative approach positions Stimdia Medical as a key player in improving respiratory care and patient management in critical settings.

Pathware is a technology company developing a digital pathology platform for point-of-care diagnostics. The platform combines computational microscopy and artificial intelligence to analyze tissue samples, enabling clinicians and pathologists to diagnose and treat diseases earlier and more precisely, with the goal of improving patient outcomes and reducing diagnostic times. Its product set includes Bioptic, an automated point-of-care biopsy assessment system, along with a sample testing platform and a sample management platform designed to streamline pathology workflows. Founded in 2017 and based in Ann Arbor, Michigan, with an additional location in Seattle, Pathware focuses on bringing computational pathology tools to the bedside to support faster, more accurate decision making in healthcare.

Cryosa is a medical technology company specializing in the development of innovative treatments for obstructive sleep apnea.

Francis Medical, Inc., established in 2018 and based in Maple Grove, Minnesota, specializes in the development of innovative medical devices utilizing water vapor technology to treat various urological cancers. The company focuses on prostate, kidney, and bladder cancers, aiming to provide minimally invasive treatments that can potentially reduce life-altering side effects common with traditional methods. Their approach involves using the thermal energy stored in sterile water vapor to ablate cancerous tissue via a simple transurethral procedure.

InterShunt, founded in 2015 and based in St Louis, Missouri, specializes in designing and developing a catheter-based minimally-invasive procedure aimed at alleviating symptoms for individuals suffering from heart failure. The company focuses on left atrial decompression as a key solution to reduce these symptoms. Their proprietary system involves an interatrial shunting device that does not require an implant or energy source, allowing doctors to lower left atrial pressure in patients with heart failure through a simple catheter procedure.

Knopp Biosciences LLC is a biotechnology company specializing in the discovery and development of innovative medicines for inflammatory and neurological diseases. Founded in 2004 and headquartered in Pittsburgh, Pennsylvania, the company focuses on addressing high-cost diseases with identifiable patient populations through validated biomarkers or genetic testing. Its clinical programs include dexpramipexole, an anti-inflammatory therapeutic aimed at modulating white blood cells, and a hematology discovery program targeting the selective arrest of eosinophil maturation for treating inflammatory conditions. Additionally, Knopp Biosciences is advancing a preclinical program aimed at activating the KCNQ2 ion channel, which is linked to neonatal encephalopathy, epilepsy, and neuropathic pain, as well as a mitochondrial discovery program that seeks to enhance mitochondrial efficiency through small molecule modulators. The company's mission is to accelerate treatment advancements, change disease trajectories, and improve patient outcomes.

BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

AEGEA Medical, Inc. is a medical technology company based in Menlo Park, California, that specializes in innovative treatments for women's health. The company has developed a water vapor ablation system, known as Mara, which is designed for the in-office treatment of heavy menstrual bleeding, specifically menorrhagia. This FDA-approved technology utilizes adaptive vapor ablation to deliver safe and effective endometrial ablation in a simple procedure that takes only minutes. AEGEA Medical aims to expand treatment options for a broader range of patients while ensuring convenience and confidence for physicians performing these office-based procedures. The company was incorporated in 2007 and continues to focus on enhancing patient outcomes in women's healthcare.

AEGEA Medical, Inc. is a medical technology company based in Menlo Park, California, that specializes in innovative treatments for women's health. The company has developed a water vapor ablation system, known as Mara, which is designed for the in-office treatment of heavy menstrual bleeding, specifically menorrhagia. This FDA-approved technology utilizes adaptive vapor ablation to deliver safe and effective endometrial ablation in a simple procedure that takes only minutes. AEGEA Medical aims to expand treatment options for a broader range of patients while ensuring convenience and confidence for physicians performing these office-based procedures. The company was incorporated in 2007 and continues to focus on enhancing patient outcomes in women's healthcare.

ATFX is a prominent Forex CFD broker that offers a diverse selection of over 300 trading products, including forex currency pairs, commodities such as precious metals and crude oil, indices, and stocks. With a global presence that spans 21 offices across regions including Europe, South America, the Middle East, Asia, Australia, and South Africa, ATFX aims to provide a comprehensive and user-friendly trading experience. The company has earned a strong reputation, reflected in its receipt of more than 80 international awards for excellence in online trading and customer service, including titles such as 'Best Fintech Forex Broker' and 'Global Forex Broker of the Year.' ATFX is recognized for its innovative online broking services platform, which facilitates seamless transactions and offers access to a variety of trading tools and resources, catering to the needs of online traders in the financial markets.

PreTel is a Canadian company based in Ontario that specializes in the development of advanced fetal monitoring systems aimed at enhancing maternal and pediatric health outcomes during labor and delivery. The company focuses on uterine electromyography (uEMG) monitoring technology, which allows for the precise identification of contraction activity in different regions of the uterus. This innovation addresses the common challenges associated with distinguishing between true and false labor, thereby reducing the need for unnecessary invasive procedures, cesarean deliveries, and prolonged neonatal intensive care. By improving the management of preterm labor and the delivery process, PreTel's solutions contribute to safer outcomes for both mothers and infants in healthcare settings.

Founded in 2015, Arrivo BioVentures specializes in developing biologics and small molecules to enhance patient care. The company focuses on efficient clinical programs, coordinating with regulatory bodies early on to expedite drug approvals.

ATFX is a prominent Forex CFD broker that offers a diverse selection of over 300 trading products, including forex currency pairs, commodities such as precious metals and crude oil, indices, and stocks. With a global presence that spans 21 offices across regions including Europe, South America, the Middle East, Asia, Australia, and South Africa, ATFX aims to provide a comprehensive and user-friendly trading experience. The company has earned a strong reputation, reflected in its receipt of more than 80 international awards for excellence in online trading and customer service, including titles such as 'Best Fintech Forex Broker' and 'Global Forex Broker of the Year.' ATFX is recognized for its innovative online broking services platform, which facilitates seamless transactions and offers access to a variety of trading tools and resources, catering to the needs of online traders in the financial markets.

PreTel is a Canadian company based in Ontario that specializes in the development of advanced fetal monitoring systems aimed at enhancing maternal and pediatric health outcomes during labor and delivery. The company focuses on uterine electromyography (uEMG) monitoring technology, which allows for the precise identification of contraction activity in different regions of the uterus. This innovation addresses the common challenges associated with distinguishing between true and false labor, thereby reducing the need for unnecessary invasive procedures, cesarean deliveries, and prolonged neonatal intensive care. By improving the management of preterm labor and the delivery process, PreTel's solutions contribute to safer outcomes for both mothers and infants in healthcare settings.

AEGEA Medical, Inc. is a medical technology company based in Menlo Park, California, that specializes in innovative treatments for women's health. The company has developed a water vapor ablation system, known as Mara, which is designed for the in-office treatment of heavy menstrual bleeding, specifically menorrhagia. This FDA-approved technology utilizes adaptive vapor ablation to deliver safe and effective endometrial ablation in a simple procedure that takes only minutes. AEGEA Medical aims to expand treatment options for a broader range of patients while ensuring convenience and confidence for physicians performing these office-based procedures. The company was incorporated in 2007 and continues to focus on enhancing patient outcomes in women's healthcare.